Time-cap Labs,

Time-Cap Laboratories, Inc., established in 1978, is a prominent pharmaceutical manufacturer headquartered in Farmingdale, New York. The company specializes in the production of generic pharmaceuticals, over-the-counter (OTC) medications, and nutritional supplements. Its product portfolio includes tablets, capsules, softgels, and other solid oral dosage forms, catering to a diverse range of therapeutic areas. Time-Cap Laboratories operates a state-of-the-art manufacturing facility in Farmingdale, New York, which is approved by the U.S. Food and Drug Administration (FDA). This facility produces over 50 unique products, including tablets, capsules, and pellets, and is recognized for its expertise in extended and delayed-release formulations and coating services.

In July 2015, Time-Cap Laboratories was acquired by Marksans Pharma, an Indian pharmaceutical company, through its wholly owned subsidiary Marksans Pharma Inc. This acquisition, valued at $28 million, provided Marksans Pharma with an established platform to expand its operations in the U.S. market. The acquisition enabled Marksans Pharma to enhance its manufacturing capabilities and product portfolio, particularly in the generic pharmaceutical sector.

Time-Cap Laboratories' distribution network is primarily centered in the United States, with its manufacturing facility in Farmingdale, New York, serving as the main hub for production and distribution. The company supplies its products to major retailers, chain drug stores, big-box retailers, and mail-order pharmacies across the country. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, Time-Cap Laboratories' extensive distribution network ensures widespread availability of its products throughout the U.S. market.

Time-Cap Laboratories functions as a pharmaceutical manufacturer specializing in generic drugs, over-the-counter (OTC) medications, and nutritional supplements. Its role in the U.S. pharmaceutical supply chain involves the production and distribution of these products to various stakeholders, including wholesalers, retailers, and pharmacies. The company's focus on generic pharmaceuticals allows it to provide cost-effective alternatives to branded medications, thereby enhancing access to essential healthcare products for consumers.

Time-Cap Laboratories' sourcing strategy exhibits a high degree of concentration, with a significant portion of its imports originating from a single supplier, Marksans Pharma Limited. This supplier concentration suggests a strategic partnership aimed at ensuring consistent product quality and supply chain efficiency. The substantial volume of imports from Marksans Pharma Limited indicates a stable and reliable relationship, which is crucial for maintaining uninterrupted product availability in the U.S. market. However, such dependency also presents potential risks, including exposure to supply chain disruptions or regulatory changes affecting the supplier. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

Time-Cap Laboratories' supply chain resilience is closely tied to its relationship with Marksans Pharma Limited, the primary supplier of its imported pharmaceutical formulations. The company's reliance on a single supplier for a significant portion of its product line may expose it to risks associated with supply chain disruptions, such as production delays, quality control issues, or regulatory challenges faced by the supplier. To bolster supply chain resilience, Time-Cap Laboratories could consider establishing relationships with additional suppliers, thereby reducing dependency on a single source and enhancing the flexibility and robustness of its supply chain.

The sourcing pattern of Time-Cap Laboratories, characterized by a high dependency on Marksans Pharma Limited, has strategic implications for both the company and potential Indian exporters. For Time-Cap Laboratories, this concentrated sourcing strategy may lead to cost efficiencies and streamlined operations but also exposes the company to risks associated with supplier dependency. For Indian exporters, the existing relationship with Marksans Pharma Limited presents an opportunity to supply Time-Cap Laboratories with additional products, thereby expanding their market reach in the U.S. pharmaceutical sector. However, any new supplier would need to meet the stringent quality and regulatory standards required by Time-Cap Laboratories and the FDA.

The U.S. Food and Drug Administration (FDA) is the primary regulatory authority overseeing the importation and marketing of pharmaceutical products in the United States. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth the legal requirements for drug products, including those imported from foreign countries. For Indian pharmaceutical products, the FDA requires that manufacturers comply with its regulations, including Good Manufacturing Practice (GMP) standards, to ensure the safety, efficacy, and quality of drugs entering the U.S. market. The FDA also conducts inspections of foreign manufacturing facilities to verify compliance with these standards.

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Manufacturers and importers must register their establishments and list their drug products with the FDA. Additionally, imported drugs must comply with FDA's standards for quality, safety, and effectiveness. The FDA recognizes various GMP certifications, including those from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications are considered acceptable by the FDA, provided they meet the agency's standards. Importers must ensure that their suppliers hold valid GMP certifications recognized by the FDA to facilitate the importation process.

Imported pharmaceutical products must adhere to FDA's quality and labeling requirements. This includes compliance with batch testing and stability requirements to ensure product safety and efficacy. Labeling must be truthful and informative, providing all necessary information in English, as per FDA regulations. Specific labeling requirements depend on the type of drug product, such as over-the-counter drugs, prescription drugs, or investigational drugs. Additionally, the FDA may require serialization of drug products to enhance traceability and prevent counterfeit drugs from entering the supply chain.

Between 2024 and 2026, the FDA has implemented several policy changes affecting the importation of pharmaceutical products from India. These changes include stricter enforcement of GMP compliance, enhanced inspection protocols for foreign manufacturing facilities, and updated labeling requirements to improve product traceability and safety. Importers and manufacturers must stay informed about these regulatory updates to ensure continued compliance and uninterrupted access to the U.S. market.

Time-Cap Laboratories' product strategy focuses on the production of generic pharmaceuticals, over-the-counter (OTC) medications, and nutritional supplements. The company's emphasis on these therapeutic areas aligns with market demand for cost-effective alternatives to branded medications and the growing consumer interest in health and wellness products. By offering a diverse range of products, Time-Cap Laboratories aims to meet the needs of various consumer segments and maintain a competitive position in the U.S. pharmaceutical market.

Time-Cap Laboratories' sourcing strategy is characterized by a high degree of concentration, with a significant portion of its imported pharmaceutical formulations sourced from Marksans Pharma Limited in India. This strategic partnership allows Time-Cap Laboratories to leverage Marksans Pharma's manufacturing capabilities and product portfolio, ensuring a consistent supply of quality products. The company's focus on sourcing from a single supplier reflects a strategic choice aimed at streamlining operations and maintaining product quality.

Based on its product mix, Time-Cap Laboratories serves the U.S. pharmaceutical market by supplying generic drugs, over-the-counter (OTC) medications, and nutritional supplements to various segments, including retail pharmacies, hospital pharmacies, and government tenders. The company's diverse product portfolio enables it to cater to a wide range of consumer needs, from everyday health and wellness products to more specialized pharmaceutical requirements.

There is a realistic opportunity for new Indian suppliers to enter Time-Cap Laboratories' sourcing strategy, particularly in therapeutic areas where the company seeks to expand its product offerings. Potential suppliers must meet FDA's stringent quality and regulatory standards, including holding recognized GMP certifications and adhering to labeling requirements. By establishing relationships with additional suppliers, Time-Cap Laboratories can diversify its product portfolio and enhance supply chain resilience.

Indian exporters seeking to supply Time-Cap Laboratories and the U.S. market must obtain FDA registration and listing for their establishments and drug products. They must also hold valid GMP certifications recognized by the FDA, such as EU GMP, WHO GMP, or PIC/S certifications. Additionally, exporters must ensure compliance with FDA's quality, labeling, and serialization requirements to facilitate the importation process.

Indian exporters interested in supplying Time-Cap Laboratories should initiate contact by providing detailed information about their product offerings, manufacturing capabilities, and compliance with FDA regulations. Participating in industry trade shows and networking events can also facilitate introductions. Once a potential partnership is identified, exporters should work closely with Time-Cap Laboratories to navigate the regulatory filing process, which includes obtaining FDA registration and listing, ensuring GMP compliance, and meeting labeling